EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Interleukin-23 (IL-23) inhibitor, mirikizumab in the treatment of ulcerative colitis (UC): a promising therapy?

Saurav Misra, Manmeet Kaur, Ashish Kumar Saranjhna

Journal of Basic and Clinical Physiology and Pharmacology · 2026

DOI: 10.1515/jbcpp-2024-0102 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Basic and Clinical Physiology and Pharmacology, 2026. Verfasst von Saurav Misra und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Kalpana Chawla Government Medical College, Karnal, Haryana, India. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Antibodies, Monoclonal, Humanized, Interleukin-23 Subunit p19, Interleukin-23. Die Arbeit nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mirikizumab is a monoclonal antibody that targets the human IL-23p19 and has been humanized with IgG4. It is currently under development for treating Crohn’s disease and ulcerative colitis. The FDA approved mirikizumab on October 26, 2023 as a highly effective treatment for ulcerative colitis, providing patients with a new option for this chronic and debilitating inflammatory bowel disease. Millions of people worldwide suffer from ulcerative colitis, and it is crucial to induce and maintain remission. However, existing therapies may not suffice in terms of efficacy or patient tolerability. Mirikizumab demonstrated a favorable safety profile during trials, with reported adverse events aligning with anticipated outcomes in the patient group. These safety results underscore the viability of mirikizumab as a well-tolerated therapeutic option for extended use. The trials data indicated that the treatment not only swiftly alleviated symptoms but also exhibited potential for sustaining remission over an extended period. This article seeks to offer a condensed overview of the noteworthy clinical trial outcomes that contributed to the development of mirikizumab, ultimately leading to its initial approval for the treatment of ulcerative colitis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeAntibodies, Monoclonal, HumanizedInterleukin-23 Subunit p19Interleukin-23Gastrointestinal AgentsHumansTreatment OutcomeAnimals

Stichwörter der Autor:innen

cytokinesmirikizumabmonoclonal antibodyulcerative colitis

Substanzen

Antibodies, Monoclonal, HumanizedInterleukin-23 Subunit p19Interleukin-23Gastrointestinal Agents

Autor:innen und Institutionen

  • Department of Pharmacology, Kalpana Chawla Government Medical College, Karnal, Haryana, India.

Zitieren

APA

Misra, S., Kaur, M., & Saranjhna, A. K. (2026). Interleukin-23 (IL-23) inhibitor, mirikizumab in the treatment of ulcerative colitis (UC): a promising therapy?. Journal of Basic and Clinical Physiology and Pharmacology. https://doi.org/10.1515/jbcpp-2024-0102

Vancouver

Misra S, Kaur M, Saranjhna AK. Interleukin-23 (IL-23) inhibitor, mirikizumab in the treatment of ulcerative colitis (UC): a promising therapy?. Journal of Basic and Clinical Physiology and Pharmacology. 2026. doi:10.1515/jbcpp-2024-0102

BibTeX
@article{Misra2026,
  author = {Misra, Saurav and Kaur, Manmeet and Saranjhna, Ashish Kumar},
  title = {Interleukin-23 (IL-23) inhibitor, mirikizumab in the treatment of ulcerative colitis (UC): a promising therapy?},
  journal = {Journal of Basic and Clinical Physiology and Pharmacology},
  year = {2026},
  doi = {10.1515/jbcpp-2024-0102}
}
Kostenlos starten →